N@N

AEGN SqueezeTrigger Price is $15.83. There is $64,535,240 That Short Sellers Still Need To Cover.

^{Published on 2012-06-11 05:40:20 - WOPRAI}
 

June 11, 2012 / M2 PRESSWIRE / BUYINS.NET / www.squeezetrigger.com is monitoring Aegion Corp (NASDAQ:AEGN) in real time and just received an alert that AEGN is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 4008400 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $15.83. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .

From August 2009 to May 2012, an aggregate amount of 7785775 shares of AEGN have been shorted for a total dollar value of $116786625. The AEGN SqueezeTrigger price of $15.83 is the volume weighted average price that all shorts are short in shares of AEGN. There is still approximately $64,535,240 of potential short covering in shares of AEGN.

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger Price for each stock that has been shorted. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of short squeeze events. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com .

Aegion Corp (NASDAQ:AEGN) - Aerogen, Inc. (Aerogen), incorporated in November 1991, is a specialty pharmaceutical company that develops drug products focusing on respiratory therapy in the acute care setting. Based on its OnQ Aerosol Generator (OnQ) for aerosolizing liquids, it has developed and commercially introduced nebulizers that optimize aerosol production for use in both the home and hospital. The Company is also developing pulmonary drug delivery products in collaboration with partner companies for respiratory therapy and systemic drug input. Aerogen's lead therapeutic product, in a Phase II clinical trial, is an aerosolized antibiotic comprising a formulation of amikacin delivered via Aerogen's Pulmonary Drug Delivery System (PDDS") for the treatment of patients on ventilators with ventilator-associated pneumonia (VAP). This Phase II clinical trial was initiated on December 28, 2004, and involves the enrollment of 108 patients at approximately 31 study sites, with each patient to be studied for 28 consecutive days.

The PDDS consists of a software-driven controller, which is capable of sensing the performance of the ventilator and aerosolizing the drug during a predetermined portion of the ventilator cycle. It incorporates an OnQ with a particle size that has been customized for the individual therapeutic application. The Company does not intend to market the PDDS as a stand-alone device, as it intends to use it exclusively for delivery of drug products in the acute care setting. Aerogen's nebulizer products include Aeroneb Portable Nebulizer System, Aeroneb Go Nebulizer and Aeroneb Professional Nebulizer System.

Aeroneb Go Nebulizer

Aeroneb Go Nebulizer received the Conformite Europeenne (CE) mark in July 2003, and received 510(k) clearance from the United states Food and Drug Administration (FDA) in November 2003. This product replaces the Aeroneb Portable Nebulizer System in the home market. The Aeroneb Go is a nebulizer developed for patients worldwide that require respiratory therapy in and away from home. It allows patients to complete their treatments with minimal wasted medication and delivers a respirable aerosol.

In June 2003, the Company made initial commercial shipments of the product to Norway via its distributor Normed, as part of a test market. In September 2003, it entered into an agreement with Medical Industries America Inc. for marketing and manufacturing of the Aeroneb Go. First commercial shipments occurred in the United States in January 2004.

Aeroneb Professional Nebulizer System

Aeroneb Professional Nebulizer System was CE marked in Europe, and FDA clearance in the United States as a general-purpose nebulizer intended to aerosolize physician-prescribed solutions for inhalation. The product is designed to improve the efficiency of drug delivery and reduce personnel and drug costs associated with inpatient care, particularly for patients on ventilators. The Aeroneb Pro can be used not only on the ventilator but also in the hospital or in an ambulance and it can also be used with both adult and children's masks. The device is autoclaveable, so it is suitable for multi-patient use, and its low residual volume allows efficient drug delivery to the lungs.

The Aeroneb Pro System is small and lightweight, allowing it to be positioned close to the patient's airway and is designed to allow the addition of medication to the nebulizer without opening the ventilator tubing. The drug is aerosolized without the use of compressed air and therefore avoids the introduction of additional air and pressure into the ventilator circuit. The Company has developed a version of the Aeroneb Pro specifically for use in animal testing laboratories, marketed as the Aeroneb Lab.

Aerogen has entered into a worldwide, non-exclusive supply agreement with Datex-Ohmeda, Inc., a division of Instrumentarium, which was acquired by GE Healthcare in October 2003. Under the agreement, Aerogen is supplying GE Healthcare with a customized version of the Aeroneb Pro for integration into future products designed for critical care. G

The SqueezeTrigger database of approximately 1 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data. Total Short Interest is the number of shares shorted but not yet covered, and is different from total short volume. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com

About SQUEEZETRIGGER.COM

WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.

SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly one billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each month's short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.

By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.

Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641